1. •Specific delivery of siRNAs

  2. •in-vivo model for neurons

  3. •Propietary nanoparticles

  4. •DNA Vaccines

 
 

nLife Therapeutics has developed key technology to support its therapeutics programs:

  1. -siRNA modifications for specific cell targeting: This capability has been assayed in-vivo and shown remarkable effectivity at a therapeutic dose, by i.c.v. and intranasal application, knocking down selected genes in serotonergic neurons in mice brain.

  2. -Improved Aptamers production: By the modification of a Blended SELEX process, nLife Therapeutics identify valuable aptamers against desired targets that are used as affinity components in its siRNA delivery platform.

  3. -Next Generation DNA Vaccines: Based in its propietary Dendrimer technology, nLife has formulated circular DNA (plasmids) as DNA vaccine with improved efficiency

Key technology supporting a nucleic acids therapeutic program